Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
With the launch of QurOne, the brand aims to redefine healthcare in the country with seamless, hassle-free patient care and hyper-coordinated workflows
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
Second interchangeable biosimilar product approved by agency
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company claims that its Empagliflozin tablets are the most affordable in India
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
Subscribe To Our Newsletter & Stay Updated
